Columvi Becomes Canada’s First Approved Bispecific Antibody for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBL)



This article gives a brief overview of Columvi (Glofitamab) and explains the basis for its approval for treating certain types of Diffuse Large B-cell lymphoma (DLBL), and patients may explore options to Buy Columvi online in India through regulated channels.

Understanding Columvi (Glofitamab)

Columvi therapy is used in the adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy, and treatment planning often includes understanding the Columvi price in India.

Glofitamab is the antibody present in the Columvi that recognizes and attaches to CD20 (protein on the surface of B cells) and to CD3 (protein on the surface of healthy T cells), and many patients also search for options to Buy glofitamab online in India after consulting their doctor. When the Columvi acts as a bridge to unite both the proteins, it eventually kills the cancer cells.

It is available in the form of injection as 2.5mg/2.5mL (1mg/1mL) per single dose vial or 10mg/10mL (1mg/1mL) per single dose vial, where dosage requirements may vary and patients often evaluate the glofitamab price in India before proceeding.

Understanding Diffuse Large B-cell Lymphoma (DLBL)

Lymphoma is a type of blood cancer that occurs in the lymphatic system. There are two types of lymphomas i.e., Hodgkin’s and Non-Hodgkin’s lymphoma. The DLBL is a form of Non-Hodgkin’s lymphoma, a fast-growing blood cancer which shows good response during the initial stages of treatment but relapses or shows a refractory disease in the later stages in 40% of the patients, where some cases may require patients to Buy Glofitamab 2.5 mg in India as part of initial dosing protocols.

Phase III STARGLO study

This is a randomized open-label research study which compared Columvi plus gemcitabine and oxaliplatin (GemOx) to MabThera®/Rituxan® (rituximab) plus GemOx in patients suffering from relapsed or refractory(R/R) DLBL to whom the autologous stem-cell transplant cannot be performed, and treatment escalation may involve patients needing to Buy Glofitamab 10 mg in India depending on clinical response. The overall survival rates showed a 41% reduction in risk of death in patients treated with Columvi plus gemcitabine and oxaliplatin (GemOx) to MabThera®/Rituxan® (rituximab) plus GemOx in the initial analysis. In the later stages, a complete response of 58.5% is analysed in patients with Columvi plus GemOx compared to patients with R-GemOx. The combination of Columvi and GemOx showed consistent safety profiles, so it was considered as a novel treatment for R/R DLBL.

Side-effects of Columvi

  1. Neurotoxicity symptoms are fatal neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity (ICANS), headache, peripheral neuropathy and dizziness.
  2. Serious infections like COVID 19 infections and sepsis.
  3. Tumor flare can cause localized pain and swelling at the sites of the lymphoma lesions and/or dyspnea from new pleural effusions.

Conclusion

For more information, visit 24/7QualityMeds.


Location: India

Comments

Post a Comment

Popular posts from this blog

Myth vs Fact: Blincyto Edition

Image
Blinatumomab (Blincyto) in India Blincyto is a Bispecific T-cell engager (BiTE) immunotherapy used for the treatment of certain B-cell precursor acute lymphoblastic leukemia (ALL). Since it works differently from chemotherapy, it has led to curiosity and confusion. These confusions lead to misconceptions to patients, so here’s the article to burst the myth and present the facts. MYTH: Blincyto ( Blinatumomab ) works for all types of leukemia FACT: Blincyto is indicated in adults and children above one month old with: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.   Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).  CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.  MYTH: Side-effects of Blincyto are sam...
Read more

Not All Immune Protection Starts with a Vaccine: What Makes Cytogam Different?

Image
Cytogam CMV 50 mg for Injection available in India  Most people are familiar with the two primary approaches used to protect the body against viral infections: vaccines and antiviral medications. Antiviral drugs work by targeting specific stages of a virus's life cycle. They interfere with the virus's ability to replicate, spread, or produce the proteins it needs to survive within the body. Vaccines, in contrast, help train the immune system to recognize and respond to a particular pathogen before an infection occurs, enabling the body to build its own defense mechanisms. However, there is a third approach that is often overlooked. It is neither a vaccine nor an antiviral drug, yet it plays an important role in protecting certain high-risk patients. This approach is known as hyperimmune globulin therapy. Understanding the Basics Hyperimmune globulin therapy provides immediate immune protection by supplying antibodies that have already been formed. Unlike vaccines, which require...
Read more

Pemigatinib in India: Availability, Pricing & Access Pathways Explained

Image
Buy pemigatinib (Pemazyre) tablets in India For patients looking for pemigatinib in India , finding the medicine can involve a different process from purchasing a conventional prescription medicine from a local pharmacy. Pemigatinib, sold under the brand name Pemazyre, is an oral targeted therapy that inhibits fibroblast growth factor receptors (FGFR1, FGFR2 and FGFR3). It is used for specific cancers in which these pathways are altered, including previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement and relapsed or refractory myeloid/lymphoid neoplasms with an FGFR1 rearrangement. In India, access can involve individual-patient importation rather than routine retail pharmacy supply. Understanding the prescription, documentation, sourcing, storage, delivery and monitoring requirements can help patients and caregivers navigate the process more confidently. The Current Situation of Pemazyre in India Why This Therapy Is N...
Read more